Company News 30 Sep 2025 Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the… Orthocell
Company News 16 Sep 2025 Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device - for use in nerve-sparing Robotic-Assisted… Orthocell
Company News 08 Sep 2025 Remplir™ Real World Evidence study delivers compelling 81% success rate Orthocell has today released interim results from a new Remplir™ Real World Evidence study, demonstrating an overall treatment success rate… Orthocell
